- Published on
Emergency and Acute Medicine – Peripartum Cardiomyopathy
Core Definition
Peripartum cardiomyopathy is a dilated cardiomyopathy that develops during the final month of pregnancy or within the first 5 months after delivery. Diagnosis requires all of the following: onset of heart failure in the defined peripartum period, no identifiable alternative cause, no preexisting cardiac disease, and objective echocardiographic evidence of systolic dysfunction. Incidence is approximately 3–5 per 10,000 live births. About half of cases recover spontaneously. Reported mortality ranges from 18% to 56%. Thromboembolic complications are more common than in other cardiomyopathies.
Risk Profile and Prognostic Indicators
Risk is increased in women older than 30 years, multiparity, multiple gestations, prolonged tocolytic therapy exceeding 4 weeks, obesity, preeclampsia, and African American race. Poor prognosis is associated with low left ventricular ejection fraction at 6 months postpartum, symptom onset more than 2 weeks after delivery, age over 30 years, African American descent, and multiparity.
Proposed Pathophysiology
The exact cause remains uncertain. Leading theories include viral myocarditis facilitated by pregnancy-related immunosuppression, autoimmune reaction to maternal or fetal antigens, maladaptive response to pregnancy-related hemodynamic stress, stress-induced cytokine activation, prolonged tocolysis, and nutritional deficiencies such as selenium deficiency.
Clinical Presentation
Common symptoms include dyspnea, orthopnea, paroxysmal nocturnal dyspnea, cough, dizziness, chest discomfort, fatigue, anorexia, and arrhythmias. History should focus on timing of symptom onset, persistent unexplained cough, excessive weight gain greater than 2–4 lb per week, prior cardiac disease, and complications in previous pregnancies. Examination findings may include jugular venous distention, gallop rhythm, mitral regurgitation murmur, loud P2, pulmonary rales, rapid-onset peripheral edema, hepatomegaly, and hepatojugular reflux.
Essential Evaluation
Chest radiography may show pulmonary venous congestion, cardiomegaly (difficult to interpret in pregnancy), and pleural effusions. Electrocardiography is nonspecific but may demonstrate left ventricular hypertrophy, left atrial enlargement, T-wave changes, ventricular ectopy (≈40%), or atrial fibrillation (≈20%).
Diagnostic Data Interpretation
Laboratory studies typically show normal electrolytes and renal function. Mild postpartum anemia may worsen dyspnea and fatigue. BNP is useful in differentiating cardiac from pulmonary causes of dyspnea; levels >100 pg/mL strongly support heart failure, while ≤50 pg/mL has a high negative predictive value. Chest imaging may demonstrate progressive pulmonary edema patterns from cephalization to interstitial and alveolar edema, sometimes mimicking pneumonia. Echocardiography confirms diagnosis by showing global ventricular dilation, wall thinning, and reduced systolic function. Diagnostic criteria include ejection fraction <45%, fractional shortening <30%, and indexed lv end-diastolic dimension>2.72 cm/m², with exclusion of valvular disease and tamponade. Endomyocardial biopsy is reserved for suspected myocarditis or consideration of immunosuppressive therapy.
Conditions to Exclude
Alternative causes of dilated cardiomyopathy include ischemia, infarction, valvular disease, chronic hypertension, familial cardiomyopathy, alcohol or drug toxicity, metabolic disorders, thyroid disease, infections, autoimmune disease, neuromuscular disorders, and mitochondrial disease. Other causes of dyspnea or edema include pulmonary embolism, pneumonia, asthma, anemia, hyperthyroidism, constrictive pericarditis, tamponade, nephrotic syndrome, and cirrhosis.
Initial and Emergency Management
Differentiate pulmonary edema from reactive airway disease early. Rapid assessment of airway, breathing, and circulation is essential. Provide supplemental oxygen, consider noninvasive ventilation, and address preload and afterload carefully.
Antepartum management includes nitrates, hydralazine, IV diuretics, amlodipine, digoxin for rate control, cautious use of carvedilol when stable, low-molecular-weight heparin when EF <35%, fetal monitoring, and invasive monitoring if unstable.
Postpartum therapy allows addition of ACE inhibitors or ARBs. Anticoagulation is frequently recommended due to high thromboembolic risk. Heparin is preferred during pregnancy; warfarin is avoided until postpartum. Refractory or severe cases may require inotropes, vasopressors, vasodilators, mechanical circulatory support, or extracorporeal membrane oxygenation. Immunosuppressive therapy may be considered if no improvement occurs after 2 weeks of optimal medical therapy, though evidence remains mixed.
Disposition Decisions
All symptomatic patients with new-onset peripartum cardiomyopathy require admission. ICU care is indicated for pulmonary edema, cardiogenic shock, or ischemia. Discharge may be considered only in carefully selected patients with mild dysfunction, established disease, rapid symptom resolution, no ischemia, and reliable close follow-up.
Follow-Up Guidance
Cardiology follow-up is mandatory. Patients should maintain adequate hydration, restrict dietary sodium, avoid alcohol, use compression stockings if needed, monitor daily weights, and seek care for rapid weight gain, worsening dyspnea, syncope, or palpitations.
Clinical Pearls and Pitfalls
Thromboembolism risk is high in pregnancy-associated cardiomyopathy. Early recognition and coordinated management with cardiology and obstetrics significantly improve outcomes.
Core Definition
Peripartum cardiomyopathy is a dilated cardiomyopathy that develops during the final month of pregnancy or within the first 5 months after delivery. Diagnosis requires all of the following: onset of heart failure in the defined peripartum period, no identifiable alternative cause, no preexisting cardiac disease, and objective echocardiographic evidence of systolic dysfunction. Incidence is approximately 3–5 per 10,000 live births. About half of cases recover spontaneously. Reported mortality ranges from 18% to 56%. Thromboembolic complications are more common than in other cardiomyopathies.
Risk Profile and Prognostic Indicators
Risk is increased in women older than 30 years, multiparity, multiple gestations, prolonged tocolytic therapy exceeding 4 weeks, obesity, preeclampsia, and African American race. Poor prognosis is associated with low left ventricular ejection fraction at 6 months postpartum, symptom onset more than 2 weeks after delivery, age over 30 years, African American descent, and multiparity.
Proposed Pathophysiology
The exact cause remains uncertain. Leading theories include viral myocarditis facilitated by pregnancy-related immunosuppression, autoimmune reaction to maternal or fetal antigens, maladaptive response to pregnancy-related hemodynamic stress, stress-induced cytokine activation, prolonged tocolysis, and nutritional deficiencies such as selenium deficiency.
Clinical Presentation
Common symptoms include dyspnea, orthopnea, paroxysmal nocturnal dyspnea, cough, dizziness, chest discomfort, fatigue, anorexia, and arrhythmias. History should focus on timing of symptom onset, persistent unexplained cough, excessive weight gain greater than 2–4 lb per week, prior cardiac disease, and complications in previous pregnancies. Examination findings may include jugular venous distention, gallop rhythm, mitral regurgitation murmur, loud P2, pulmonary rales, rapid-onset peripheral edema, hepatomegaly, and hepatojugular reflux.
Essential Evaluation
Chest radiography may show pulmonary venous congestion, cardiomegaly (difficult to interpret in pregnancy), and pleural effusions. Electrocardiography is nonspecific but may demonstrate left ventricular hypertrophy, left atrial enlargement, T-wave changes, ventricular ectopy (≈40%), or atrial fibrillation (≈20%).
Diagnostic Data Interpretation
Laboratory studies typically show normal electrolytes and renal function. Mild postpartum anemia may worsen dyspnea and fatigue. BNP is useful in differentiating cardiac from pulmonary causes of dyspnea; levels >100 pg/mL strongly support heart failure, while ≤50 pg/mL has a high negative predictive value. Chest imaging may demonstrate progressive pulmonary edema patterns from cephalization to interstitial and alveolar edema, sometimes mimicking pneumonia. Echocardiography confirms diagnosis by showing global ventricular dilation, wall thinning, and reduced systolic function. Diagnostic criteria include ejection fraction <45%, fractional shortening <30%, and indexed lv end-diastolic dimension>2.72 cm/m², with exclusion of valvular disease and tamponade. Endomyocardial biopsy is reserved for suspected myocarditis or consideration of immunosuppressive therapy.
Conditions to Exclude
Alternative causes of dilated cardiomyopathy include ischemia, infarction, valvular disease, chronic hypertension, familial cardiomyopathy, alcohol or drug toxicity, metabolic disorders, thyroid disease, infections, autoimmune disease, neuromuscular disorders, and mitochondrial disease. Other causes of dyspnea or edema include pulmonary embolism, pneumonia, asthma, anemia, hyperthyroidism, constrictive pericarditis, tamponade, nephrotic syndrome, and cirrhosis.
Initial and Emergency Management
Differentiate pulmonary edema from reactive airway disease early. Rapid assessment of airway, breathing, and circulation is essential. Provide supplemental oxygen, consider noninvasive ventilation, and address preload and afterload carefully.
Antepartum management includes nitrates, hydralazine, IV diuretics, amlodipine, digoxin for rate control, cautious use of carvedilol when stable, low-molecular-weight heparin when EF <35%, fetal monitoring, and invasive monitoring if unstable.
Postpartum therapy allows addition of ACE inhibitors or ARBs. Anticoagulation is frequently recommended due to high thromboembolic risk. Heparin is preferred during pregnancy; warfarin is avoided until postpartum. Refractory or severe cases may require inotropes, vasopressors, vasodilators, mechanical circulatory support, or extracorporeal membrane oxygenation. Immunosuppressive therapy may be considered if no improvement occurs after 2 weeks of optimal medical therapy, though evidence remains mixed.
Disposition Decisions
All symptomatic patients with new-onset peripartum cardiomyopathy require admission. ICU care is indicated for pulmonary edema, cardiogenic shock, or ischemia. Discharge may be considered only in carefully selected patients with mild dysfunction, established disease, rapid symptom resolution, no ischemia, and reliable close follow-up.
Follow-Up Guidance
Cardiology follow-up is mandatory. Patients should maintain adequate hydration, restrict dietary sodium, avoid alcohol, use compression stockings if needed, monitor daily weights, and seek care for rapid weight gain, worsening dyspnea, syncope, or palpitations.
Clinical Pearls and Pitfalls
Thromboembolism risk is high in pregnancy-associated cardiomyopathy. Early recognition and coordinated management with cardiology and obstetrics significantly improve outcomes.
0 Comments
